Business

CURE Pharmaceutical [OTCQB:CURR] Licenses Cannabis Extraction Patents to Vanguard Scientific

CURE Pharmaceutical [OTCQB:CURR] Licenses Cannabis Extraction Patents to Vanguard Scientific.

articleAvenir Wellness Solutions Inc.February 12, 20203/company/avenir-wellness-solutions-inc/news/cure-pharmaceutical-otcqbcurr-licenses-cannabis-extraction-patents-to-vanguard-scientific
CURE Pharmaceutical [OTCQB:CURR] Licenses Cannabis Extraction Patents to Vanguard Scientific

About this update from Avenir Wellness Solutions Inc.

[{"type":"text","content":"\n LOS ANGELES, Feb. 12, 2020 (GLOBE NEWSWIRE) -- CURE Pharmaceutical (OTC: CURR), an innovative drug delivery and development company, today announced a licensing and collaboration agreement with Vanguard Scientific Systems, Inc., a premier provider of equipment, systems and performance solutions servicing the botanical extraction industry, including both the MIDAS XII, a next-generation GMP compliant supercritical CO2 extraction technology, as well as industrially scaled CO2 facility solutions. The license gives Vanguard the right to practice CURE’s patented cannabis extraction methods, providing customer confidence in choosing Vanguard’s portfolio of extraction manufacturers.  “This license agreement gives operational freedom to a leader in the supercritical fluid extraction industry who is committed to pharma-grade standards continuing our powered by Cure licensing strategy,” said Rob Davidson, CEO of CURE Pharmaceutical. “Building on this license, we will collaborate with Vanguard Scientific experts to expand the licensed patent estate to cover the most recent advances in the field.” CURE has granted Vanguard rights to its portfolio of issued and pending process and composition patents for isolating cannabinoids using an advanced supercritical fluid extraction technology utilizing carbon dioxide as the solvent. While the patents cover the incorporation of cannabis extracts into multiple dosage forms, CURE has reserved all rights to applying these methods in oral thin film. \"CURE is a leader in cannabinoid drug delivery innovation, and this license and collaboration agreement will give our customers peace of mind when selecting our extraction solutions,\" said Matthew Anderson, CEO of Vanguard Scientific. \"Working with CURE, we intend to further our traction in the marketplace by jointly pursuing a focused patenting strategy in order to offer its clients a broader range of protected and defensible separation capabilities.\" The purpose developed suite of Vanguard Scientific Quality Products and Solutions are available to clients globally. Vanguard integration specialists provide clients with an initial gap analysis, including a review of current operations, to assure their goals and desired product targets are appropriately planned for. With quality systems developed to meet ma...

More updates from Avenir Wellness Solutions Inc.